Alnylam gets EU approval for Amvuttra in heart disorder treatment

June 09, 2025 08:24 AM PDT | By EODHD

Google News:

Alnylam gets EU approval for Amvuttra in heart disorder treatment — Image source: Kalkine Media

Recent News

Kalkine : Nasdaq Composite Moves Amid Affirm Options Surge

Kalkine: Stock Market Reacts Mildly After House Passes Trump Tax Bill...

Kalkine:Indexdjx Dji Rises on Trade Talks and Confidence Boost

Kalkine: Intel Drops Amid Rivals’ Launches Dow Jones Industrial Averag...

[Amyloidosis bleeding] Hailshadow/iStock via Getty Images * Alnylam Pharmaceuticals (NASDAQ:ALNY [https://seekingalpha.com/symbol/ALNY]) said on Monday that the European Commission has approved its RNAi therapeutic, Amvuttra, to treat hereditary transthyretin amyloidosis in adults with cardiomyopathy. * This adds a new indication for the drug [https://seekingalpha.com/pr/20129731-alnylam-receives-european-commission-approval-for-amvuttra-vutrisiran-for-the-treatment-of], which was previously approved in March 2025 by the U.S. FDA and Brazil's Health Regulatory Agency, for treating cardiomyopathy associated with wild-type or hereditary ATTR amyloidosis in adults. MORE ON ALNYLAM PHARMACEUTICALS * Why Alnylam Could Outperform In The Transthyretin Amyloidosis With Cardiomyopathy Field [https://seekingalpha.com/article/4790824-why-alnylam-could-outperform-in-transthyretin-amyloidosis-with-cardiomyopathy-field] * Alnylam Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4780610-alnylam-pharmaceuticals-inc-2025-q1-results-earnings-call-presentation] * Alnylam Pharmaceuticals, Inc.

(ALNY) Q1 2025 Earnings Call Transcript [https://seekingalpha.com/article/4780609-alnylam-pharmaceuticals-inc-alny-q1-2025-earnings-call-transcript] * Alnylam posts new Phase 3 data for heart disease therapy Amvuttra [https://seekingalpha.com/news/4449855-alnylam-posts-new-data-heart-disease-drug] * Alnylam reiterates 2025 guidance with projected 36% growth in TTR franchise revenues [https://seekingalpha.com/news/4439287-alnylam-reiterates-2025-guidance-with-projected-36-percent-growth-in-ttr-franchise-revenues]

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.